About: Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
Creator	Inal, Jameel
source	Medline; PMC
abstract	The novel strain of coronavirus that appeared in 2019, SARS-CoV-2, is the causative agent of severe respiratory disease, COVID-19, and the ongoing pandemic. As for SARS-CoV that caused the SARS 2003 epidemic, the receptor on host cells that promotes uptake, through attachment of the spike (S) protein of the virus, is angiotensin-converting enzyme 2 (ACE2). In a recent article published by Batlle et al. (Clin. Sci. (Lond.) (2020) 134, 543–545) it was suggested that soluble recombinant ACE2 could be used as a novel biological therapeutic to intercept the virus, limiting the progression of infection and reducing lung injury. Another way, discussed here, to capture SARS-CoV-2, as an adjunct or alternative, would be to use ACE2(+)-small extracellular vesicles (sEVs). A competitive inhibition therapy could therefore be developed, using sEVs from engineered mesenchymal stromal/stem cells (MSCs), overexpressing ACE2.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1042/cs20200623
bibo:pmid	32542396
has license	cc-by-nc-nd
sha1sum (hex)	f6af1b2ded99effabc04f4ee0c54bb5c5c8624b5
schema:url	https://doi.org/10.1042/cs20200623
resource representing a document's title	Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
has PubMed Central identifier	PMC7298154
has PubMed identifier	32542396
schema:publication	Clin Sci (Lond)
resource representing a document's body	covid:f6af1b2ded99effabc04f4ee0c54bb5c5c8624b5#body_text
is schema:about of	named entity 'Batlle' named entity 'attachment' named entity 'SARS-CoV' named entity 'alternative' named entity 'expressing' named entity 'INFECTION' named entity 'SCI' named entity 'Sci.' named entity 'suggested' named entity 'ACE2' named entity 'causative' named entity 'adjunct' named entity 'published' named entity 'SARS-CoV-2' named entity 'engineered' named entity '2003' named entity 'extracellular vesicles' named entity 'SARS-CoV-2' named entity 'host cells' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'mesenchymal' named entity 'epidemic' named entity 'angiotensin-converting enzyme 2' named entity 'ACE2' named entity 'SARS-CoV' named entity 'lung' named entity 'ACE2' named entity 'virus' named entity 'immune cells' named entity 'A549' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'proteases' named entity 'brain injury' named entity 'lung' named entity 'preclinical' named entity 'surface receptor' named entity 'lung' named entity 'ACE2' named entity 'pro-inflammatory' named entity 'ACE2' named entity 'ACE2' named entity 'COVID' named entity 'ACE2' named entity 'type II alveolar cells' named entity 'tumour' named entity 'Intranasal' named entity 'cell membranes' named entity 'organ' named entity 'competitive inhibition' named entity 'ACE2' named entity 'anti-inflammatory' named entity 'CD4' named entity 'phagocytosed' named entity 'Acute Respiratory Distress Syndrome' named entity 'lung' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'leucocyte' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'stoichiometry' named entity 'interact' named entity 'proof of concept' named entity 'binding avidity' named entity 'SARS-CoV-2' named entity 'ischaemia' named entity 'monocytes' named entity 'ARDS' named entity 'alveolar type II cells' named entity 'kidney' named entity 'virion' named entity 'ACE2' named entity 'COVID' named entity 'lungs' named entity 'COVID' named entity 'therapeutic proteins' named entity 'clinical setting' named entity 'immunosuppressive' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software